ストックスクリーナーアプリを入手
23.49
0.17%
0.04
Pfizer Inc (PFE) 最新ニュース
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WSAU
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - GlobeNewswire
Pfizer Combo Halves Death Risk in BRAF V600E Cancer - Mirage News
US CDC keeps COVID vaccine option for healthy children - marketscreener.com
Pfizer Reports Positive Results in Late Stage Trial for Colorectal Cancer Treatment - Insider Monkey
Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate’ - WREX
Former Pfizer Atty, Motley Rice Adviser, Joins DiCello Levitt - Law360
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50% - Benzinga
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC - Yahoo Finance
Pfizer: colorectal cancer mortality halved - marketscreener.com
Pfizer posts trial win for colorectal cancer drug (PFE:NYSE) - Seeking Alpha
Pfizer Says Braftovi Combination Regimen Halved Death Risk in Colorectal Cancer Study - marketscreener.com
Pfizer's Oral Obesity Drug FlopA Symptom Of A Deeper Pipeline Problem - Seeking Alpha
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Pfizer
Pfizer Says Braftovi Combination Regimen Met Trial's Dual Primary Endpoint - marketscreener.com
Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show - MedCity News
Pfizer’s Braftovi Doubles Survival in Advanced Colorectal Cancer - Bloomberg
The World Market for Smoking Cessation & Nicotine De-Addiction Products 2025-2030: Precision Counseling, Targeted Pharmacogenomic Therapies, and Resilient Supply Chains Present Lucrative Opportunities - GlobeNewswire Inc.
$3.94 Bn IV Hydration Therapy Markets - GlobeNewswire Inc.
Why this $400-million money manager is ditching Pfizer and buying the tech dip - The Globe and Mail
FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines - Hematology Advisor
Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes - Yahoo Finance
Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges - simplywall.st
Pfizer Jolted Higher On A Merck-Rivaling Deal. Is It A Buy? - Investor's Business Daily
Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Are Investors Undervaluing Pfizer (PFE) Right Now? - Nasdaq
Down 63%, Should You Buy the Dip on Pfizer? - AOL.com
Berenberg Bank Cuts Pfizer Price Target to $25 From $28, Maintains Hold Rating - marketscreener.com
5 Rock-Solid Dividend Stocks Under $50 With Room to Run - 24/7 Wall St.
Old COVID tweet lands Pfizer in new trouble with PMCPA - pharmaphorum
PFIZER INC : Berenberg reaffirms its Neutral rating - marketscreener.com
Acute Myeloid Leukemia Market Detailed Analysis and Forecast - openPR.com
Pfizer (PFE) Stock Slides Over 2%, Hits Day’s Low in Afternoon Trading - Daily Chhattisgarh News
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners - Yahoo Finance
U.S. Vaccine Market Set to Witness Robust ExpansionPfizer, Moderna - openPR.com
Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development - marketscreener.com
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline - Seeking Alpha
US drops COVID vaccine recommendation for healthy kids, pregnant women - marketscreener.com
Mixed options sentiment in Pfizer with shares up 0.88% - TipRanks
US drops COVID vaccine recommendations for healthy children, pregnant women - marketscreener.com
Sleep Aids Market Generated Opportunities, Future Scope - openPR.com
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Enamine to Enable Access to Selected Pfizer Reference Compounds to Support the Global Research CommunityMETRO - METRO - NEWS CHANNEL NEBRASKA
Specialty Injectable Generics Market Is Booming So Rapidly - openPR.com
Immunostimulant Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com
Chlorphenamine Maleate API Market Trends, Demand, and Future Outlook | Pfizer Inc., Novartis AG, Sanofi S.A. - openPR.com
Pfizer, Inc. (PFE) Stock Analysis: Evaluating a 26.50% Potential Upside Amidst Challenges - DirectorsTalk Interviews
Investing In The Promising PD1/VEGF Bispecific; Pfizer And Instil Could Be Good Candidates - Seeking Alpha
Pfizer (PFE) Secures $1.25B Cancer Drug Licensing Deal - GuruFocus
Was Jim Cramer Right About Pfizer Inc. (PFE)? - MSN
25,379 Shares in Pfizer Inc. (NYSE:PFE) Bought by PVG Asset Management Corp - InsuranceNewsNet
0.93%
1.64%
大文字化:
|
ボリューム (24 時間):